Visto che fai il maestrino, leggi l’articolo allora
A multicentre, adaptive, randomised, placebo-controlled, double-blind phase 3 trial was set up to evaluate the efficacy and safety of vaccination against SARS-CoV-2 with 2 doses of SOBERANA-02 (FINLAY-FR-2) -subsequently referred to as So2-and with a three dose heterologous scheme adding SOBERANA-Plus (FINLAY-FR-1A) to the former -hereafter So2P. Participants were recruited from March 8th to March 31st, 2021 and received, with intervals of 28 days, either the two or three doses scheme or placebo.
La vaccinazione che chiamano eterologa è con un terzo shot di soberana, ma aggiornato.